Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerard Piñol-Ripoll

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|March 14, 2026
Anticholinergic burden and its relationship with cognitive impairment in a neuropsychiatric unitMaría Ruiz-Julián, Gerard Piñol-Ripoll
Patient Preference and Adherence|April 22, 2025
Clinicians' Perspectives of Twice-Weekly Rivastigmine Patches for Alzheimer's Disease Treatment in Spain: The VIITAL 2S StudyGerard Piñol-Ripoll, Mario Salas Carrillo,
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|May 19, 2026
[Translated article] Anticholinergic burden and its relationship with cognitive impairment in a neuropsychiatric unitMaría Ruiz-Julián, Gerard Piñol-Ripoll
Frontiers in Psychology|April 25, 2025
Cognitive therapies and their impact on neuropsychiatric symptoms in mild cognitive impairment or dementia: a scoping reviewBeatriz Lara-Consuegra, Anna Carnes-Vendrell, Paula Torres-Hidalgo, et al.
Medicina Clinica|June 22, 2010
[Validation of the ABCDI and ABCD2I scales in the registry of patients with transient ischemic attacks from Lleida (REGITELL) Spain]Francisco Purroy, Gerard Piñol-Ripoll, Alejandro Quílez, et al.
Geroscience|November 24, 2023
Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer's diseaseFarida Dakterzada, Mariona Jové, Raquel Huerto, et al.
Peerj|July 14, 2018
Study of community-living Alzheimer's patients' adherence to the Mediterranean diet and risks of malnutrition at different disease stagesMariona Rocaspana-García, Joan Blanco-Blanco, Alfonso Arias-Pastor, et al.
Aging and Disease|May 17, 2023
Changes in Plasma Neutral and Ether-Linked Lipids Are Associated with The Pathology and Progression of Alzheimer's DiseaseFarida Dakterzada, Mariona Jové, Raquel Huerto, et al.
Current Aging Science|October 8, 2019
Usefulness of CSF Biomarkers in Predicting the Progression of Amnesic and Nonamnesic Mild Cognitive Impairment to Alzheimer's DiseaseRicard L Ortega, Farida Dakterzada, Alfonso Arias, et al.
Molecular Brain|November 16, 2018
proBDNF is modified by advanced glycation end products in Alzheimer's disease and causes neuronal apoptosis by inducing p75 neurotrophin receptor processingCatherine Fleitas, Gerard Piñol-Ripoll, Pau Marfull, et al.
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|March 14, 2026
Anticholinergic burden and its relationship with cognitive impairment in a neuropsychiatric unitMaría Ruiz-Julián, Gerard Piñol-Ripoll
Patient Preference and Adherence|April 22, 2025
Clinicians' Perspectives of Twice-Weekly Rivastigmine Patches for Alzheimer's Disease Treatment in Spain: The VIITAL 2S StudyGerard Piñol-Ripoll, Mario Salas Carrillo,
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|May 19, 2026
[Translated article] Anticholinergic burden and its relationship with cognitive impairment in a neuropsychiatric unitMaría Ruiz-Julián, Gerard Piñol-Ripoll
Frontiers in Psychology|April 25, 2025
Cognitive therapies and their impact on neuropsychiatric symptoms in mild cognitive impairment or dementia: a scoping reviewBeatriz Lara-Consuegra, Anna Carnes-Vendrell, Paula Torres-Hidalgo, et al.
Medicina Clinica|June 22, 2010
[Validation of the ABCDI and ABCD2I scales in the registry of patients with transient ischemic attacks from Lleida (REGITELL) Spain]Francisco Purroy, Gerard Piñol-Ripoll, Alejandro Quílez, et al.
Geroscience|November 24, 2023
Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer's diseaseFarida Dakterzada, Mariona Jové, Raquel Huerto, et al.
Peerj|July 14, 2018
Study of community-living Alzheimer's patients' adherence to the Mediterranean diet and risks of malnutrition at different disease stagesMariona Rocaspana-García, Joan Blanco-Blanco, Alfonso Arias-Pastor, et al.
Aging and Disease|May 17, 2023
Changes in Plasma Neutral and Ether-Linked Lipids Are Associated with The Pathology and Progression of Alzheimer's DiseaseFarida Dakterzada, Mariona Jové, Raquel Huerto, et al.
Current Aging Science|October 8, 2019
Usefulness of CSF Biomarkers in Predicting the Progression of Amnesic and Nonamnesic Mild Cognitive Impairment to Alzheimer's DiseaseRicard L Ortega, Farida Dakterzada, Alfonso Arias, et al.
Molecular Brain|November 16, 2018
proBDNF is modified by advanced glycation end products in Alzheimer's disease and causes neuronal apoptosis by inducing p75 neurotrophin receptor processingCatherine Fleitas, Gerard Piñol-Ripoll, Pau Marfull, et al.
Pageof 11